Clinical Trial Update: Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing first-line palliative chemotherapy regimens EOX vs mDCF in advanced HER2-negative gastric cancer has completed; results discuss efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Eloxatin (oxaliplatin)
• Etoposide (Etoposide)
• Platinol (cisplatin)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Jagiellonian University | Conditions: HER2 Negative Gastric Cancer | Phase 3 | Status: COMPLETED